Drug intelligence / Profile preview

amikacin + clarithromycin + azithromycin + tigecycline + omadacycline + tedizolid

Development stage: Preclinical
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Inhalation, Intravenous, Oral

Overview

This combination represents a multidrug susceptibility profile and potential therapeutic regimen consisting of the antibiotics amikacin, clarithromycin, azithromycin, tigecycline, omadacycline, and tedizolid [3246]. These agents are primarily utilized in the management of difficult-to-treat, multidrug-resistant atypical mycobacterial infections, such as those caused by *Mycobacterium abscessus* [3246]. Treatment of *M. abscessus* typically requires a multidrug approach tailored to the specific susceptibility profile of the clinical isolate to prevent the emergence of resistance [3246].

Targets

30S A-site (Bacterial ribosomal 30S A-site)NPET (Bacterial 50S ribosomal subunit 23S rRNA peptide exit tunnel)Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on amikacin + clarithromycin + azithromycin + tigecycline + omadacycline + tedizolid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amikacin + clarithromycin + azithromycin + tigecycline + omadacycline + tedizolid.